World Alzheimer's Day 2021: The Power of Knowledge

World Alzheimer's Day is an international campaign organised by Alzheimer's Disease International to raise awareness and highlight issues faced by people affected by dementia. It takes place every year on September 21st and is the focus of World Alzheimer's Month.

Dementia is one of the biggest challenges we face, with nearly 50 million people living with dementia worldwide. Yet 2 out of every 3 people globally believe there is little or no understanding of dementia in their countries.The impact of World Alzheimer's Month is growing, but the stigmatisation and misinformation that surrounds dementia remains a global problem. To tackle this challenge, we need to collaborate and share best practice with one another.

In support of this year’s theme – ‘Know dementia, know Alzheimer's’ - Elsevier presents a curated, open access collection of over 70 journal articles and book chapters focused on shining a light on the warning signs of dementia and the importance of a timely diagnosis.


Heliyon, Volume 6, November 2020

In this study Casuarictin, Saponins, and Enoxolone emerged as promising herbal therapeutics against Alzheimer's disease.

Heliyon, Volume 6, August 2020

Serotonin or 5-hydroxytryptamine (5-HT) is primarily involved in the regulation of learning and memory. Pathological changes in metabolism or functional imbalance of 5-HT has been associated with Alzheimer's disease (AD). The hypothesis tested is that in peripheral blood, markers of the serotonergic pathway can be used as a diagnostic tool for AD.

iScience, Volume 23, 24 April 2020

Multifaceted Aβ toxicity activates premature apoptosis and neuronal death in Alzheimer's Disease (AD). Berberine is modified to nontoxic and polyphenolic multifunctional derivative (Ber-D). Ber-D modulates Aβ aggregation, metal toxicity, ROS, oxidative and biomolecules damage. Study revealed mitochondrial protection and downregulation of apoptosis markers.

Heliyon, Volume 6, February 2020

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive decline in cognitive function. Intracerebroventricular injection of streptozotocin (icv-STZ) has been used as an experimental model of Sporadic AD (SAD) in rodents and represents a promising tool for etiopathogenic analysis and evaluation of new therapeutic proposals for AD. The icv-STZ model shows many aspects of SAD abnormalities, resulting in decreased brain glucose and energy metabolism, cognitive impairment, oxidative stress, neuronal loss, and amyloid angiopathy.

iScience, Volume 19, 27 September 2019

A sialic acid mimetic increases the uptake of Alzheimer peptide into microglia. Crystal structure of cell surface receptor CD33 bound to the sialic acid mimetic. Crystal structure of unliganded CD33 and mutagenesis studies revealed key residues. CD33 carbohydrate-binding site is a pharmacophore for Alzheimer drug development.

iScience, Volume 16, 28 June 2019

ICV-injected Aβ-Th1 T cells elevate MHCII+ microglial cells around plaques. T cells undergo stimulation by microglia and facilitate amyloid clearance. Microglia-T cell interactions orchestrate immune mechanisms regulating Alzheimer's Disease pathology

iScience, Volume 9, 30 November 2018

AMP-activated protein kinase (AMPK) is rapidly activated following synaptic activation. AMPK stimulates neuronal glycolysis and oxidative respiration, i.e., metabolic plasticity. Metabolic plasticity ensures the expression of IEGs and long-term memory formation. AMPK deregulation, as in Alzheimer disease, prevents metabolic plasticity response.


Journal of the American Academy of Dermatology,
Volume 84, Issue 3,
Pages 790-792,

Exploration of the assocation between psoriasis and dementia.

Volume 7, Issue 8,

Vanadium (V) toxicity depends on its oxidation state; it seems that vanadium pentoxide (V2O5) is the most toxic to the living cells. It has been reported that oral administration induces changes in motor activity and learning; in rats, I.P. administration increases lipid peroxidation levels in the cerebellum and the concentration of free radicals in the hippocampus and cerebellum.

The Lancet Healthy Longevity, Volume 2, August 2021

This study is the first systematic review and meta-analysis to compare mortality rates and survival outcomes between people with Alzheimer's disease, people with non-Alzheimer's dementias, and people without dementia.